Ninety-three patients with colorectal cancer who developed moderate-to-severe COM ( WHO grade 1 ) during any cycle of chemotherapy using FOLFOX , FOLFIRI , and/or XELOX treatment were randomly assigned to receive either TJ-14 ( n = 46 ) or placebo ( n = 47 ) .